443 related articles for article (PubMed ID: 32503398)
21. Stimuli-responsive nanoparticles based on poly acrylic derivatives for tumor therapy.
Li K; Zang X; Cheng M; Chen X
Int J Pharm; 2021 May; 601():120506. PubMed ID: 33798689
[TBL] [Abstract][Full Text] [Related]
22. Multi-stimuli responsive hollow MnO
Xu X; Duan J; Liu Y; Kuang Y; Duan J; Liao T; Xu Z; Jiang B; Li C
Acta Biomater; 2021 May; 126():445-462. PubMed ID: 33785453
[TBL] [Abstract][Full Text] [Related]
23. Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting.
Liu JF; Jang B; Issadore D; Tsourkas A
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Nov; 11(6):e1571. PubMed ID: 31241251
[TBL] [Abstract][Full Text] [Related]
24. Programmed near-infrared light-responsive drug delivery system for combined magnetic tumor-targeting magnetic resonance imaging and chemo-phototherapy.
Feng Q; Zhang Y; Zhang W; Hao Y; Wang Y; Zhang H; Hou L; Zhang Z
Acta Biomater; 2017 Feb; 49():402-413. PubMed ID: 27890732
[TBL] [Abstract][Full Text] [Related]
25. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
26. Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers".
Layek B; Singh J
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31861113
[TBL] [Abstract][Full Text] [Related]
27. Light-Responsive and Dual-Targeting Liposomes: From Mechanisms to Targeting Strategies.
Agiba AM; Arreola-Ramírez JL; Carbajal V; Segura-Medina P
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338380
[TBL] [Abstract][Full Text] [Related]
28. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.
Gullotti E; Yeo Y
Mol Pharm; 2009; 6(4):1041-51. PubMed ID: 19366234
[TBL] [Abstract][Full Text] [Related]
29. Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release.
Tang Q; Yu B; Gao L; Cong H; Song N; Lu C
Curr Med Chem; 2018; 25(16):1837-1866. PubMed ID: 29332566
[TBL] [Abstract][Full Text] [Related]
30. Stimuli-responsive mesoporous silica nanoparticles: A custom-tailored next generation approach in cargo delivery.
Salve R; Kumar P; Ngamcherdtrakul W; Gajbhiye V; Yantasee W
Mater Sci Eng C Mater Biol Appl; 2021 May; 124():112084. PubMed ID: 33947574
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Drug Delivery and Therapeutics.
Hatakeyama H
Chem Pharm Bull (Tokyo); 2017; 65(7):612-617. PubMed ID: 28674332
[TBL] [Abstract][Full Text] [Related]
32. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions.
Moradi Kashkooli F; Jakhmola A; Hornsby TK; Tavakkoli JJ; Kolios MC
J Control Release; 2023 Mar; 355():552-578. PubMed ID: 36773959
[TBL] [Abstract][Full Text] [Related]
33. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
Koning GA; Krijger GC
Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
[TBL] [Abstract][Full Text] [Related]
34. Strategies To Design and Synthesize Polymer-Based Stimuli-Responsive Drug-Delivery Nanosystems.
Qin X; Li Y
Chembiochem; 2020 May; 21(9):1236-1253. PubMed ID: 31889379
[TBL] [Abstract][Full Text] [Related]
35. Fluorescent carbon dot-gated multifunctional mesoporous silica nanocarriers for redox/enzyme dual-responsive targeted and controlled drug delivery and real-time bioimaging.
Wang Y; Cui Y; Zhao Y; He B; Shi X; Di D; Zhang Q; Wang S
Eur J Pharm Biopharm; 2017 Aug; 117():105-115. PubMed ID: 28363599
[TBL] [Abstract][Full Text] [Related]
36. Internal stimuli-responsive nanocarriers for controlled anti-cancer drug release: a review.
Shaik BB; Katari NK; Jonnalagadda SB
Ther Deliv; 2023 Sep; 14(9):595-613. PubMed ID: 37877308
[TBL] [Abstract][Full Text] [Related]
37. Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy.
Vaghasiya K; Ray E; Singh R; Jadhav K; Sharma A; Khan R; Katare OP; Verma RK
Mater Sci Eng C Mater Biol Appl; 2021 Apr; 123():112027. PubMed ID: 33812642
[TBL] [Abstract][Full Text] [Related]
38. Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade.
Sohail M; Guo W; Li Z; Xu H; Zhao F; Chen D; Fu F
Curr Med Chem; 2021; 28(19):3753-3772. PubMed ID: 33019919
[TBL] [Abstract][Full Text] [Related]
39. Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy.
Dinakar YH; Karole A; Parvez S; Jain V; Mudavath SL
Life Sci; 2022 Dec; 310():121133. PubMed ID: 36306866
[TBL] [Abstract][Full Text] [Related]
40. Biomolecular Corona Affects Controlled Release of Drug Payloads from Nanocarriers.
Sharifi S; Caracciolo G; Mahmoudi M
Trends Pharmacol Sci; 2020 Sep; 41(9):641-652. PubMed ID: 32713606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
